Expanded approval enables the use of magnetic resonance imaging (MRI) with both implants at 3.0 Tesla (3%). Patients implanted with the neuromodulation systems for obstructive sleep apnea (OSA) can now undergo high-resolution 3T MRI scans under specific conditions.

The FDA approved expanded, full-body compatibility for 1.5T scans in July 2022. This approval enables even stronger, higher-resolution imaging for users of Inspire therapy.